Dicloxacillin is a semisynthetic penicillinase-resistant penicillin antibiotic.
Uses
Dicloxacillin shares the uses of other penicillinase-resistant penicillins and generally is used only in the treatment of infections caused by, or suspected of being caused by, susceptible penicillinase-resistant staphylococci. Oral dicloxacillin should not be used for the initial treatment of severe, life-threatening infections, including endocarditis, but may be used as follow-up after therapy with a parenteral penicillinase-resistant penicillin (e.g., nafcillin, oxacillin). For specific information on the uses of dicloxacillin, see Uses in the Penicillinase-Resistant Penicillins General Statement 8:12.16.12.
Dosage and Administration
Reconstitution and Administration
Dicloxacillin sodium is administered orally at least 1 hour before or 2 hours after meals. Although the drug also has been given parenterally by slow IV injection or infusion or by IM injection, a parenteral dosage form is no longer commercially available in the US. Oral dicloxacillin should not be used for the initial treatment of severe infections and should not be relied on in patients with nausea, vomiting, gastric dilatation, cardiospasm, or intestinal hypermotility.
Dosage
Dosage of dicloxacillin sodium is expressed in terms of dicloxacillin. Dosage of the drug should be adjusted according to the type and severity of infection.
Adult Dosage
The usual adult oral dosage of dicloxacillin for the treatment of mild to moderate infections caused by susceptible penicillinase-producing staphylococci is 125 mg every 6 hours. For more severe infections, the usual adult oral dosage of dicloxacillin is 250 mg every 6 hours; higher dosage may be necessary depending on the severity of the infection.
Pediatric Dosage
Children weighing 40 kg or more may receive the usual adult dosage of dicloxacillin. In children who weigh less than 40 kg, the usual oral dosage of dicloxacillin for the treatment of mild to moderate infections caused by susceptible penicillinase-producing staphylococci is 12. mg/kg daily given in divided doses every 6 hours.
The usual oral dosage for the treatment of more severe infections is 25 mg/kg daily given in divided doses every 6 hours; higher dosage may be necessary depending on the severity of the infection.If dicloxacillin is used in neonates, they should be monitored closely for clinical and laboratory evidence of toxic or adverse effects, and serum concentrations of the drug should be determined frequently and appropriate reductions in dosage and frequency of administration made when indicated. (See Cautions: Pediatric Precautions.)
The American Academy of Pediatrics (AAP) suggests that children older than 1 month of age receive oral dicloxacillin in a dosage of 25-50 mg/kg daily in 4 divided doses for the treatment of mild to moderate infections; the AAP states that the oral drug is inappropriate for severe infections. Some clinicians suggest that, when dicloxacillin is used as follow-up therapy to parenteral penicillinase-resistant penicillin therapy in the treatment of acute or chronic osteomyelitis caused by susceptible staphylococci, children should receive an oral dosage of 50-100 mg/kg daily given in divided doses every 6 hours.
If oral anti-infective therapy is used in the treatment of osteomyelitis, compliance must be assured and some clinicians suggest that serum bactericidal titers (SBTs) be used to monitor adequacy of therapy and to adjust dosage. (See Uses: Staphylococcal Infections, in the Penicillinase-Resistant Penicillins General Statement 8:12.16.12.) Duration of Therapy The duration of dicloxacillin therapy depends on the type and severity of infection and should be determined by the clinical and bacteriologic response of the patient. Dicloxacillin therapy usually should be continued for at least 48 hours after cultures are negative and the patient becomes afebrile and asymptomatic.
For severe staphylococcal infections, therapy should be continued for at least 14 days; more prolonged therapy is necessary for the treatment of osteomyelitis, endocarditis, or other metastatic infections. When oral dicloxacillin is used as follow-up therapy to parenteral penicillinase-resistant therapy in the treatment of acute osteomyelitis, the drug generally is given for 3-6 weeks or until the total duration of parenteral and oral therapy is at least 6 weeks; when used as follow-up therapy in the treatment of chronic osteomyelitis, the drug generally is given for at least 1-2 months and has been given for as long as 1-2 years.
Dosage in Renal Impairment
Adjustment of dicloxacillin dosage in patients with renal impairment generally is unnecessary.
Cautions
Adverse Effects
Adverse effects reported with dicloxacillin are similar to those reported with other penicillinase-resistant penicillins. For information on adverse effects reported with penicillinase-resistant penicillins, see Cautions in the Penicillinase-Resistant Penicillins General Statement 8:12.16.12.
Precautions and Contraindications
Dicloxacillin is contraindicated in patients who are hypersensitive to any penicillin. Dicloxacillin shares the toxic potentials of the penicillins, including the risk of hypersensitivity reactions, and the usual precautions of penicillin therapy should be observed. Prior to initiation of therapy with dicloxacillin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other drugs.
There is clinical and laboratory evidence of partial cross-allergenicity among penicillins and other b-lactam antibiotics including cephalosporins and cephamycins. Renal, hepatic, and hematologic systems should be evaluated periodically during prolonged therapy with dicloxacillin.
Because adverse hematologic effects have occurred during therapy with penicillinase-resistant penicillins, white blood cell (WBC) count and differential should be performed prior to initiation of therapy and 1-3 times weekly during therapy. In addition, urinalysis should be performed and BUN, serum creatinine, AST (SGOT), and ALT (SGPT) concentrations should be determined prior to and periodically during therapy. Patients should be advised to discontinue dicloxacillin and notify their clinicians if they develop shortness of breath, wheezing, rash, mouth irritation, black tongue, sore throat, nausea, vomiting, diarrhea, fever, swollen joints, or any unusual bleeding or bruising during therapy with the drug.
For a more complete discussion of these and other precautions associated with the use of dicloxacillin, see Cautions: Precautions and Contraindications, in the Penicillinase-Resistant Penicillins General Statement 8:12.16.12.
Pediatric Precautions
Elimination of penicillins is delayed in neonates because of immature mechanisms for renal excretion, and abnormally high serum concentrations of the drugs may occur in this age group. If dicloxacillin is used in neonates, they should be monitored closely for clinical and laboratory evidence of toxic or adverse effects, and serum concentrations of the drug should be determined frequently and appropriate reductions in dosage and frequency of administration made when indicated.
Pregnancy and Lactation
Safe use of penicillinase-resistant penicillins during pregnancy has not been definitely established. Clinical experience with use of penicillins during pregnancy in humans has not revealed evidence of adverse effects on the fetus.
However, there are no adequate and controlled studies using penicillinase-resistant penicillins in pregnant women, and dicloxacillin should be used during pregnancy only when clearly needed. Because dicloxacillin is distributed into milk, the drug should be used with caution in nursing women. Spectrum Based on its spectrum of activity, dicloxacillin is classified as a penicillinase-resistant penicillin.
For information on the classification of penicillins based on spectra of activity, see the Preface to the General Statements on Penicillins 8:12.16. Like other penicillinase-resistant penicillins, dicloxacillin is resistant to inactivation by staphylococcal penicillinases and is active against many penicillinase-producing strains of Staphylococcus aureus and S. epidermidis that are resistant to other commercially available penicillins.
For specific information on the spectrum of activity of dicloxacillin and resistance to the drug, see the sections on Spectrum and on Resistance in the Penicillinase-Resistant Penicillins General Statement 8:12.16.12.
Pharmacokinetics
In all studies described in the Pharmacokinetics section, dicloxacillin was administered as the sodium salt; dosages and concentrations of the drug are expressed in terms of dicloxacillin.
Absorption
Dicloxacillin is resistant to inactivation in the presence of acidic gastric secretions and is rapidly but incompletely absorbed from the GI tract. In healthy, fasting adults, 35-76% of an orally administered dose of dicloxacillin is absorbed from the GI tract and peak serum concentrations of the drug are generally attained within 0.5-2 hours. Presence of food in the GI tract generally decreases the rate and extent of absorption of dicloxacillin.
Following oral administration of a single 500-mg dose of dicloxacillin in fasting adults, peak serum concentrations of the drug average 10-18 µg/mL; serum concentrations of the drug decline rapidly and are generally low 6 hours after the drug is administered. In fasting adults who receive a single 250-mg oral dose of dicloxacillin as a capsule, serum concentrations of the drug average 2.9-3, 4.6-5.5,3-5.6, and 1.5-1.7 µg/mL at 30 minutes, 1 hour, 2 hours, and 4 hours, respectively, after the dose. In one study in children with acute osteomyelitis who received oral dicloxacillin in a dosage of 100 mg/kg daily given in divided doses every 6 hours, serum concentrations of the drug ranged from 12-40 µg/mL 1 hour after dosing and 6.5-20 µg/mL 3 hours after dosing.
Distribution
Dicloxacillin is distributed into bone, bile,pleural fluid, ascitic fluid, and synovial fluid. In one study in children 2-16 years of age with acute osteomyelitis who received dicloxacillin IM in a dosage of 50 mg/kg daily, dicloxacillin concentrations in bone ranged from 1.8-21. µg/g and concurrent serum concentrations of the drug ranged from 7-9 µg/mL in samples taken 1-3 hours after a dose. In children 7 months to 14 years of age with suppurative arthritis who received a single oral dicloxacillin dose of 25 mg/kg, dicloxacillin concentrations in synovial fluid obtained 2 hours after the dose were 70% of concurrent serum concentrations; synovial fluid concentrations averaged 9.5 µg/mL and serum concentrations averaged 13. µg/mL. Like other penicillins, only minimal concentrations of dicloxacillin are attained in CSF. Dicloxacillin is 95-99% bound to serum proteins. Dicloxacillin reportedly distributes into amniotic fluid in therapeutic concentrations following usual dosages. The drug also crosses the placenta and is distributed into milk. Following oral administration of a single 250-mg dose of dicloxacillin in lactating women, milk concentrations of the drug were 0.1-0. µg/mL 2 and 4 hours after the dose and undetectable 6 hours after the dose.
Elimination
The serum half-life of dicloxacillin in adults with normal renal function is 0.6-0.8 hours. In one study in children 2-16 years of age, the serum half-life of the drug averaged 1.9 hours. Dicloxacillin is partially metabolized to active and inactive metabolites. In one study following administration of a single 500-mg oral dose of dicloxacillin, 10% of the absorbed drug was hydrolyzed to penicilloic acids which are microbiologically inactive.
Dicloxacillin is also hydroxylated to a small extent to a microbiologically active metabolite which appears to be slightly less active than dicloxacillin. Dicloxacillin and its metabolites are rapidly excreted in urine mainly by tubular secretion and glomerular filtration. The drug is also partly excreted in feces via biliary elimination. Following oral administration of a single 250-mg, 500-mg, or 1-g dose of dicloxacillin in adults with normal renal function, 31-65% of the dose is excreted in urine as unchanged drug and active metabolites within 6-8 hours; approximately 10-20% of this is the active metabolite. The serum half-life of dicloxacillin is slightly prolonged in patients with impaired renal function and has been reported to range from 1-2. hours in patients with severe renal impairment.
Serum concentrations of dicloxacillin are higher and the serum half-life longer in neonates than in older children. Patients with cystic fibrosis eliminate dicloxacillin approximately 3 times faster than healthy individuals. In one study following oral administration of a single 6.25-mg/kg dose of the drug, peak serum concentrations and areas under the serum concentration-time curves (AUCs) were, on average, 2.5 times lower in patients with cystic fibrosis than in healthy individuals. Patients with cystic fibrosis had renal clearances of the drug averaging 282 mL/minute per 1.73 m while healthy individuals had renal clearances averaging 95 mL/minute per 1.73 m. Dicloxacillin is only minimally removed by hemodialysis or peritoneal dialysis.
Chemistry and Stability
Chemistry
Dicloxacillin is a semisynthetic penicillinase-resistant penicillin. Dicloxacillin, like cloxacillin (no longer commercially available in the US) and oxacillin, is an isoxazolyl penicillin. Dicloxacillin is commercially available as the monohydrate sodium salt. Potency of dicloxacillin sodium is expressed in terms of dicloxacillin. Each mg of dicloxacillin sodium contains not less than 850 µg of dicloxacillin. Dicloxacillin sodium occurs as a white to off-white, crystalline powder. The drug is freely soluble in water. Dicloxacillin sodium has a pKa of 2.7-2.8. Each 250-mg capsule of dicloxacillin contains approximately 0.6 mEq of sodium.
Stability
Commercially available dicloxacillin sodium capsules should be stored in tight containers at a temperature less than 40°C, preferably between 15-30°C. For further information on chemistry and stability, mechanism of action, spectrum, resistance, pharmacokinetics, uses, cautions, drug interactions, laboratory test interferences, and dosage and administration of dicloxacillin sodium, see the Penicillinase-Resistant Penicillins General Statement 8:12.16.12.
Preparations
Dicloxacillin Sodium Oral Capsules 250 mg (of dicloxacillin) Dicloxacillin Sodium, Sandoz Teva 500 mg (of dicloxacillin) Dicloxacillin Sodium, Sandoz Teva